Clinical Trial Update: A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating oral insulin to reduce liver fat in type 2 diabetes patients with nonalcoholic steatohepatitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis
• Type 2 Diabetes Mellitus

Drugs mentioned

• Oramed oral insulin (insulin (oral formulation))

Snippet

Sponsor: Oramed, Ltd. | Conditions: Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Status: COMPLETED | Results posted: 2024-03-29